Law Firm Probes Drugmaker for 401(k) Missteps

A New York law firm is investigating whether fiduciaries of the GlaxoSmithKline 401(k) plan violated the Employee Retirement Income Security Act of 1974 (ERISA).

A news release from the Stull, Stull & Brody firm said it is looking into whether the company ran afoul of ERISA by not disclosing its true operating condition to participants and beneficiaries. Those disclosures included information about the safety of Avandia, a diabetes drug.

Other potential ERISA issues include offering GlaxoSmithKline ADRs as an investment option under the plans when it was not prudent to do so, and/or by allowing an imprudent overconcentration of company stock in the Company’s 401(k) plans.

Never miss a story — sign up for PLANADVISER newsletters to keep up on the latest retirement plan adviser news.

The drug has been under government scrutiny since 2007 into allegations it increases risks of heart problems.

More information about the probe can be obtained by calling 800-337-4983 or via e-mail at ssbny@aol.com.

Driscoll Appointed as Senior Consultant at MHK Group

Michael Driscoll has joined the MHK Group, a National Retirement Partners member firm, at its Milwaukee, Wisconsin office.  

Driscoll has over thirty years of experience with plan sponsors in the Midwest, according to a recent press release. His previous work includes sales and marketing roles for the Principal Financial group and Prudential Financial, Inc.

 Driscoll has also acted as a retirement plan consultant, most recently with Alpha Investment Consulting Group, LLC. 

For more stories like this, sign up for the PLANADVISERdash daily newsletter.

«